The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Indirect comparison of elranatamab in MagnetisMM-3 versus real-world treatment regimens
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses an indirect comparison of outcomes for patients with multiple myeloma (MM) treated with elranatamab in the MagnetisMM-3 trial (NCT04649359) versus real-world treatment regimens. The analysis indicates that elranatamab provides a greater frequency and longer duration of response in patients compared to other regimens, making it a potential option for triple-class exposed (TCE) patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we’re presenting at EHA an analysis that essentially took data from MagnetisMM-3, which is the main trial for elranatamab and compare with real-world data for different regimens that are commonly used in different parts of the world, acknowledging that practice varies from country to country based on drug availability, preferences and other things. And what we’ve seen consistently is when you take real-world patients who have a similar profile of the patients who participate in MagnetisMM-3 around different countries around the world in Europe and the US, you see that consistently there is a greater frequency of responses and longer duration of response that we see with elranatamab, when compared to kind of real-world multiplicity of regimens using throughout...
So we’re presenting at EHA an analysis that essentially took data from MagnetisMM-3, which is the main trial for elranatamab and compare with real-world data for different regimens that are commonly used in different parts of the world, acknowledging that practice varies from country to country based on drug availability, preferences and other things. And what we’ve seen consistently is when you take real-world patients who have a similar profile of the patients who participate in MagnetisMM-3 around different countries around the world in Europe and the US, you see that consistently there is a greater frequency of responses and longer duration of response that we see with elranatamab, when compared to kind of real-world multiplicity of regimens using throughout. So this further strengthens the case for elranatamab as an option for patients who have particularly triple-class exposed disease who are in need of further therapy, of this agent being superior to any combination that is commonly currently used that includes monoclonal antibodies, PIs, and IMiDs.
Read more...
